Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
New tricuspid valve OK for US trial | Drug shows clear long-term cardiac amyloid survival | Faster PFA ablations
Wednesday, April 8, 2026
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

Long-term cardiac amyloidosis survival benefits seen in extension acoramidis trial

Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy. 
 

READ MORE >
Prem Soman, MD, director of the Cardiac Amyloidosis Center and nuclear cardiology, and associate chief of cardiology at the University of Pittsburgh Medical Center Heart and Vascular Institute presented the late-breaking results from the long-term survival benefits and disease stabilization with the drug acoramidis in patients with transthyretin amyloid cardiomyopathy at ACC 2026.
Share on Twitter Share on Facebook Share on Linkedin

Long-term cardiac amyloidosis survival benefits seen in extension acoramidis trial

Share on Twitter Share on Facebook Share on Linkedin
Prem Soman, MD, director of the Cardiac Amyloidosis Center and nuclear cardiology, and associate chief of cardiology at the University of Pittsburgh Medical Center Heart and Vascular Institute presented the late-breaking results from the long-term survival benefits and disease stabilization with the drug acoramidis in patients with transthyretin amyloid cardiomyopathy at ACC 2026.
Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.  
READ MORE >

FDA clears way for IDE pivotal trial of the Topaz tricuspid valve replacement system

The TRiCares Topaz uses a unique two-stent frame valve prosthesis for better sealing and flexibility.

READ MORE >
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to conduct a pivotal clinical trial for TRiCares Topaz transcatheter tricuspid valve replacement (TTVR) system in the U.S. The TTVR system uses two stent frames, one for the valve and one to engage the annulus with a membrane shirt between them to enable flexing of the outer ring to better seal against regurgitation.expansing stents
Share on Twitter Share on Facebook Share on Linkedin

FDA clears way for IDE pivotal trial of the Topaz tricuspid valve replacement system

Share on Twitter Share on Facebook Share on Linkedin
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to conduct a pivotal clinical trial for TRiCares Topaz transcatheter tricuspid valve replacement (TTVR) system in the U.S. The TTVR system uses two stent frames, one for the valve and one to engage the annulus with a membrane shirt between them to enable flexing of the outer ring to better seal against regurgitation.expansing stents
The TRiCares Topaz uses a unique two-stent frame valve prosthesis for better sealing and flexibility.
READ MORE >

Johnson & Johnson launches faster PFA system in Europe

The new version of the PFA system is five times faster than the current catheter to improve workflow.

READ MORE >
Johnson & Johnson announced the launch of its new Varipulse Pro pulsed field ablation (PFA) system in Europe following CE mark approval. It is five times faster at ablation delivery at a cooler temperature than the previous version.
Share on Twitter Share on Facebook Share on Linkedin

Johnson & Johnson launches faster PFA system in Europe

Share on Twitter Share on Facebook Share on Linkedin
Johnson & Johnson announced the launch of its new Varipulse Pro pulsed field ablation (PFA) system in Europe following CE mark approval. It is five times faster at ablation delivery at a cooler temperature than the previous version.
The new version of the PFA system is five times faster than the current catheter to improve workflow.
READ MORE >

Featured Articles

Deepak Bhatt discusses some of the most impactful trials at ACC 2026

Bhatt describes a mix of drug, device and strategy trials pointing to advances in cardiovascular science.
 

READ MORE >
To unpack the large number of lat-breaking trials at the American College of Cardiology 2026 meeting, Cardiovascular Business spoke in the above video interview with Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, director of the Mount Sinai Fuster Heart Hospital, who highlighted several studies he felt had the most scientific impact. This included a mix of drug, device and strategy trials pointing to advances in cardiology. #ACC #ACC26
Share on Twitter Share on Facebook Share on Linkedin

Deepak Bhatt discusses some of the most impactful trials at ACC 2026

Share on Twitter Share on Facebook Share on Linkedin
To unpack the large number of lat-breaking trials at the American College of Cardiology 2026 meeting, Cardiovascular Business spoke in the above video interview with Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, director of the Mount Sinai Fuster Heart Hospital, who highlighted several studies he felt had the most scientific impact. This included a mix of drug, device and strategy trials pointing to advances in cardiology. #ACC #ACC26
Bhatt describes a mix of drug, device and strategy trials pointing to advances in cardiovascular science. 
READ MORE >

Screening and treatment for chronic kidney disease in heart disease patients needs to be expanded

The risk associated with under-recognized CKD emerged early, highlighting the need for screening soon after a CAD diagnosis so that cardio-renal protective drugs can be started much earlier.

READ MORE >
Damaged Organ
Share on Twitter Share on Facebook Share on Linkedin

Screening and treatment for chronic kidney disease in heart disease patients needs to be expanded

Share on Twitter Share on Facebook Share on Linkedin
Damaged Organ
The risk associated with under-recognized CKD emerged early, highlighting the need for screening soon after a CAD diagnosis so that cardio-renal protective drugs can be started much earlier.
READ MORE >

Arizona cardiology practice paying $3.85M to resolve lawsuit after data breach

The 2023 incident potentially gave an attacker access to the names, addresses and Social Security numbers of thousands of heart patients.

READ MORE >
money cybersecurity ransomware health IT data breach hacker
Share on Twitter Share on Facebook Share on Linkedin

Arizona cardiology practice paying $3.85M to resolve lawsuit after data breach

Share on Twitter Share on Facebook Share on Linkedin
money cybersecurity ransomware health IT data breach hacker
The 2023 incident potentially gave an attacker access to the names, addresses and Social Security numbers of thousands of heart patients.
READ MORE >

Cardiologist was fired for speaking out about racist texts, private jet misuse, lawsuit claims

An interventional cardiologist believes he was targeted and terminated for being outspoken about a series of incidents at his hospital. 

READ MORE >
A gavel and a stethoscope
Share on Twitter Share on Facebook Share on Linkedin

Cardiologist was fired for speaking out about racist texts, private jet misuse, lawsuit claims

Share on Twitter Share on Facebook Share on Linkedin
A gavel and a stethoscope
An interventional cardiologist believes he was targeted and terminated for being outspoken about a series of incidents at his hospital. 
READ MORE >

Hospital sues cardiology practice for alleged breach of contract, ending years-long partnership

The cardiovascular care of thousands of Missouri patients is suddenly up in the air. The heart of the issue is a practice's alleged interest in opening up a new private equity-backed clinic.  

READ MORE >
broken relationship broken contract
Share on Twitter Share on Facebook Share on Linkedin

Hospital sues cardiology practice for alleged breach of contract, ending years-long partnership

Share on Twitter Share on Facebook Share on Linkedin
broken relationship broken contract
The cardiovascular care of thousands of Missouri patients is suddenly up in the air. The heart of the issue is a practice's alleged interest in opening up a new private equity-backed clinic.  
READ MORE >

In Other News

FTC warns Tennessee of coming price hikes if it rushes to remove restrictions on hospital chain

The state legislature is mulling over the passage of two bills: one that would eliminate Ballad’s status as a protected monopoly, and another that would remove the Certificate of Need, a barrier that forces healthcare entities to submit expansion proposals to regulators for approval. The issue, the FTC says, is related to timing. 

READ MORE >
Federal Trade Comission FTC Sign logo
Share on Twitter Share on Facebook Share on Linkedin

FTC warns Tennessee of coming price hikes if it rushes to remove restrictions on hospital chain

Share on Twitter Share on Facebook Share on Linkedin
Federal Trade Comission FTC Sign logo
The state legislature is mulling over the passage of two bills: one that would eliminate Ballad’s status as a protected monopoly, and another that would remove the Certificate of Need, a barrier that forces healthcare entities to submit expansion proposals to regulators for approval. The issue, the FTC says, is related to timing. 
READ MORE >

Interventional radiologist 1st in world to deliver newly approved cancer treatment

The completion of the first treatment represents a "significant milestone" for patients with liver cancer, the IR who led the procedure says.

READ MORE >
liver cancer
Share on Twitter Share on Facebook Share on Linkedin

Interventional radiologist 1st in world to deliver newly approved cancer treatment

Share on Twitter Share on Facebook Share on Linkedin
liver cancer
The completion of the first treatment represents a "significant milestone" for patients with liver cancer, the IR who led the procedure says.
READ MORE >

Healthcare agencies mellow on medical cannabis as CMS launches Medicare hemp pilot

The Centers for Medicare & Medicaid Services unveiled a new program for alternative payment model participants that would allow clinicians to use products containing CBD as part of patient care plans. In response, the Food and Drug Administration vowed not to further restrict the sale of oral hemp products.

READ MORE >
cannabis weed marijuana heart health doctor cardiologist
Share on Twitter Share on Facebook Share on Linkedin

Healthcare agencies mellow on medical cannabis as CMS launches Medicare hemp pilot

Share on Twitter Share on Facebook Share on Linkedin
cannabis weed marijuana heart health doctor cardiologist
The Centers for Medicare & Medicaid Services unveiled a new program for alternative payment model participants that would allow clinicians to use products containing CBD as part of patient care plans. In response, the Food and Drug Administration vowed not to further restrict the sale of oral hemp products.
READ MORE >

Medicare delays prior authorization pilot program for key interventional radiology service

CMS officially announced the move on April 6, with it applying to the Wasteful and Inappropriate Service Reduction (WISeR) Model. 

READ MORE >
The Medicare Physician Fee Schedule again has reductions for payments physicians receive. Medicare Money
Share on Twitter Share on Facebook Share on Linkedin

Medicare delays prior authorization pilot program for key interventional radiology service

Share on Twitter Share on Facebook Share on Linkedin
The Medicare Physician Fee Schedule again has reductions for payments physicians receive. Medicare Money
CMS officially announced the move on April 6, with it applying to the Wasteful and Inappropriate Service Reduction (WISeR) Model. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Medtech giant makes big move | The world’s top hospitals for heart surgery | New CPT codes | PET vs. SPECT | TAVR tech recalled
AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme
Trimed Popup